Cost-Effective Therapy for Multiple Myeloma

A recent analysis showed which therapy option as the most cost-effective in pretreated multiple myeloma? 


A. Daratumumab monotherapy

B. Pomalidomide plus dexamethasone

C. Carfilzomib monotherapy

D. Lenalidomide plus dexamethasone


Researchers reported that the use of pomalidomide plus low-dose dexamethasone yielded comparable life-years and quality-adjusted life years gained with daratumumab and carfilzomib as well as lower or comparable costs than daratumumab (-$8,919) and carfilzomib (-$195). To read the full study, click here.